My Cosmetics Shipment Was Detained: What Importers, Brands, and Distributors Need to Know About FDA Enforcement on Beauty and Personal Care Products.

You have been importing the same product line that sells well. Your supplier has been reliable. The formulation is the same one that moved through customs without a problem on your last three shipments. Then you get the call from your freight forwarder that nobody wants:

“The shipment has been detained, the FDA is holding it, and the clock for a response is already running.”

That scenario plays out more often than most people in the beauty and personal care industry realize. And it tends to catch importers off guard not because they were doing something obviously wrong, but because you are operating in a space where the Food and Drug Administration (“FDA”) enforcement has become significantly more aggressive over the past few years. The regulatory framework has changed, FDA’s authority has expanded, and the compliance obligations that apply to cosmetics today are different from those that many importers may have been operating under when their current supplier relationships were established

Cosmetics imported into the United States (“U.S.”) include everything from skincare, makeup, hair care, nail products, lip products, fragrances, sunscreens, or any other product intended to be applied to the human body, it is subject to FDA regulations and requirements that do not automatically align with what is legal and accepted in the country where it was made.

What has not changed is that the importer of record is the party that answers for what arrives at the border. Not the foreign manufacturer. Not the freight forwarder. You.

The Regulatory Shift Most Importers Missed.

For most of its history, FDA's authority over cosmetics was relatively limited. Something significant changed in December 2022 that many cosmetics importers still have not fully absorbed into how they operate.

Congress passed the Modernization of Cosmetics Regulation Act (“MoCRA”), and it fundamentally expanded the FDA's authority over cosmetics in ways that have direct implications for every import transaction. The agency can now compel mandatory recalls of cosmetic products it determines pose a safety risk. MoCRA established a specific mandatory recall authority for certain cosmetic products when the statutory conditions are met. That distinction matters because it shifts the risk calculation for every cosmetic import decision, which means a cosmetic product that makes it through the border and into U.S. commerce and is later found to be non-compliant does not simply get refused at the border. It can be pulled from commerce entirely, at the importer's expense.

The agency also gained new authority around facility registration and product listing requirements, adverse event reporting, and enhanced access to safety records. MoCRA also established new requirements relating to safety substantiation, records, and other aspects of cosmetic oversight. What this means practically is that the compliance baseline for cosmetics entering the United States today is higher than it was when many currently active supplier relationships were established. Products and supply chains that worked fine before MoCRA may have exposure now that did not exist then. Facility registration and product listing also should not be confused with FDA approval; FDA expressly states that registration and listing are not an approval program.

When the FDA Detains a Shipment Without Even Opening the Box.

One of the most disorienting experiences for a cosmetics importer is receiving a detention notice for a shipment the FDA has not physically examined. This is referred to as Detention Without Physical Examination (“DWPE”). This is exactly what it sounds like:

the FDA detains a shipment at the U.S. border without physically examining that particular shipment, based on documented prior evidence of violations from the same manufacturer or supplier.

In other words, if your supplier or the manufacturer your product came from has a documented history of violations with the FDA, the agency can place them on an import alert. Once that happens, covered shipments may be detained at the U.S. border without physical examination under the applicable import alert, regardless of whether the specific lot in question has any issues. It does not matter that your specific lot was tested and passed internal quality checks. It does not matter that your last five shipments from the same facility cleared without issue. The existence of a prior violation can subject subsequent shipments within the scope of an import alert to DWPE, requiring the importer to establish compliance through the procedures applicable to that alert.

As of September 2026, the FDA has active import alerts specifically for cosmetics covering adulterated products and ingredients, color additive violations, and microbiological contamination, including current DWPE alerts. These are not dormant alerts sitting in a database somewhere. They are current FDA import alerts that may be applied to covered shipments arriving at U.S. ports.

What makes DWPE particularly difficult to navigate is that getting out from under it is not as simple as providing test results or quality certificates for the detained shipment. The FDA has specific procedures and specific evidentiary requirements for releasing a shipment subject to DWPE, and those requirements differ depending on which import alert the shipment is caught under. The importer who approaches this process without understanding how it works, or who submits documentation that does not address what the FDA is actually looking for, may delay release or limit the procedural options available for addressing the detention.

The Cosmetic-Drug Line and The Boundary That Moves Based on What You Say.

Something that trips up cosmetics importers more than almost anything else is not contamination or ingredient violations, it is the line between a cosmetic and a drug under U.S. law. In most countries, that distinction is determined primarily by the formulation meaning what the product contains, while in the United States, it is determined primarily by the claims such as what the product says it does. Under U.S. law, the analysis turns significantly on the product’s intended use, and claims about what the product does can be important evidence of that intended use.

For example:

• A moisturizer is a cosmetic, but a moisturizer that claims to repair damaged skin cells, stimulate collagen production, or produce any kind of structural change in the skin may be a drug.

• A shampoo is a cosmetic, but a shampoo that claims to treat dandruff is a drug.

• Sunscreen, when marketed with claims to protect against sunburn or otherwise protect against ultraviolet radiation, is generally regulated as an over-the-counter (“OTC”) drug under FDA regulations.

Why does this matter for importers?

Because importing a drug into the U.S. triggers an entirely different regulatory framework from importing a cosmetic. Drug manufacturing facilities have to meet Current Good Manufacturing Practice (“CGMP”) requirements that go well beyond what cosmetics require. Drug products need to satisfy OTC monograph or pre-market approval requirements. And if a product is being imported as a cosmetic while making drug claims on the label, in the product literature, on the foreign supplier's website, it can be detained under an FDA import alert for unapproved new drugs. That alert, Import Alert 66-41, was updated as recently as September 11, 2026 and is actively applied when a product presented as a cosmetics is determined to be an unapproved drug.

The implication for importers is straightforward but not simple. Every claim on every label, every marketing statement associated with a product you import, and every piece of promotional material your supplier provides is part of the compliance picture. That is a level of scrutiny that most importers are not applying before their shipments move.

Why Compliance in Another Country Does Not Protect You Here.

This is the piece of information that surprises people most, and it comes up in almost every cosmetics enforcement situation we see.

The European Union prohibits over a thousand ingredients in cosmetic products. The United States prohibits a much shorter list. That does not mean U.S. requirements are easier to satisfy, it means the specific things the FDA prohibits or restricts are different from what a European or South Korean or Brazilian manufacturer is calibrated to avoid. A product formulated to full EU, South Korean, or Brazilian compliance may still contain a color additive, a preservative, or a restricted ingredient that the FDA does not permit in a cosmetic sold in the United States. In other words, cosmetic products that may be developed to satisfy the regulatory requirements of their home markets does not automatically translate to FDA compliance. And the FDA does not give credit for foreign regulatory approval. A product that cleared its home country's cosmetics authority with no issues can still be detained, refused entry, or subject to enforcement action once it arrives at a U.S. port.

Importers who rely on their supplier's representation that a product is “internationally compliant” or “approved in the foreign markets” are relying on something that simply does not address the question the FDA is asking. By the time the issue is discovered at the border, the options are limited and the costs are already accumulating.

What Happens in the Hours After a Detention Notice Arrives.

The response window after an FDA detention notice is limited, and that clock does not stop while you call your supplier, while you consult your freight forwarder, or while you try to understand what the detention notice actually means. The matter is time-sensitive from the moment the notice is issued, although the applicable response deadline and procedure can depend on the nature of the detention.

What the FDA needs from you in that window depends entirely on why the shipment was detained, and that reason is not always obvious from the face of the notice. The nature of the response that gives you the best chance of securing release is different depending on whether you are dealing with a DWPE situation, a labeling issue, a color additive concern, a drug claim problem, or a microbiological contamination flag. Submitting the wrong evidence does not simply fail to resolve the detention. It can actually delay resolution or limit procedural options that would otherwise have been available.

If the FDA ultimately refuses entry, the shipment may need to be re-exported or destroyed. The costs for storage, re-export freight, and destruction all fall on the importer. And if the issue is at the supplier or manufacturer level rather than the product level, the problem does not end with that shipment. Subsequent entries from the same facility may face additional scrutiny or detention, depending on the applicable import alert and whether the underlying issue has been resolved with the FDA.

Switching suppliers or manufacturer is a business decision with compliance implications of its own. The new supplier or manufacturer's facility registration status, operating practices, and history with FDA all become relevant to your next import entry.

Under U.S. import law, the importer of record bears significant responsibility for the accuracy of the entry and compliance with applicable U.S. import requirements. That responsibility does not shift to the foreign supplier or manufacturer because the formulation was developed there. It does not shift to the freight forwarder because they prepared the entry documents. It does not shift to the testing laboratory that issued a certificate of analysis before the product shipped.

When the FDA detains or refuses a cosmetics shipment, the importer may face immediate operational and financial consequences of the detention or refusal. If additional enforcement proceedings follow, the identity of the respondent and the applicable consequences will depend on the nature of the alleged violation and the enforcement mechanism involved. The importer may have legal claims against the supplier under the terms of their contract, but those are separate disputes that play out separately and on a different timeline from the FDA enforcement matter, which is already moving.

The importers who navigate cosmetics enforcement situations successfully are not necessarily the ones with the most rigorously compliant products. They are the ones who understood their exposure before a detention forced the question, who had legal counsel involved early enough to shape the response rather than react to consequences, and who had the contractual and documentary infrastructure in place to give them meaningful options when something went wrong.

Successful importers also understand that FDA detention risk should be addressed before a shipment ever reaches the border. They do not wait for FDA to detain a shipment before reviewing the product marketing claims. Preventive compliance measures implemented before shipment can reduce avoidable regulatory problems, minimize delays, and give the importer a clearer path to respond if FDA does raise an issue.

The goal is not simply to respond effectively when FDA detains a shipment. The goal is to identify and address the risk before the shipment is tendered for export.

If your cosmetics shipment has been detained or refused, if you have received an FDA detention notice, or if you import beauty and personal care products and want an honest assessment of what your compliance exposure actually looks like under the current regulatory environment, contact us today for a confidential consultation.

We also work with customs brokers, freight forwarders, beauty brands, distributors, retailers, and referring attorneys whose clients are dealing with FDA cosmetics import enforcement matters.

• 1. Why would the FDA detain a cosmetics shipment?

  The FDA may detain a shipment for reasons including suspected adulteration, labeling issues, color additive violations, microbiological contamination, or concerns that a product is actually an unapproved drug.

• 2. What is Detention Without Physical Examination (DWPE)?

  DWPE allows the FDA to detain certain covered shipments without physically examining the specific shipment, based on the criteria of an applicable import alert.

• 3. Does FDA registration mean my cosmetic product is approved?

  No. FDA expressly distinguishes facility registration and product listing from FDA approval. Registration and listing are regulatory requirements, not an approval program.

• 4. Can a cosmetic product be treated as a drug?

  Yes. Classification depends significantly on the product's intended use, and claims about what a product does can be important evidence of that intended use.

• 5. Is sunscreen regulated as a cosmetic?

  Sunscreen marketed with claims to protect against sunburn or ultraviolet radiation is generally regulated as an over-the-counter (“OTC”) drug under FDA requirements.

• 6. Does compliance with EU or other foreign regulations protect a product from FDA enforcement?

  No. Compliance with another country's requirements does not necessarily establish compliance with U.S. FDA requirements.

• 7. Who bears responsibility when a cosmetics shipment is detained?

  The importer of record bears significant responsibility for the accuracy of the entry and compliance with applicable U.S. import requirements.

• 8. What happens if the FDA refuses entry of a cosmetics shipment?

  The shipment may need to be re-exported or destroyed, with associated storage, transportation, and destruction costs potentially falling on the importer.

• 9. Can a prior FDA problem affect future shipments?

  Yes. Depending on the applicable import alert and circumstances, subsequent shipments from the same facility may face additional scrutiny or detention.

• 10. When should an importer address FDA compliance issues?

  Ideally, before the shipment reaches the U.S. border. Preventive compliance can help identify regulatory risks before they become shipment-level enforcement problems.

This article is intended for informational purposes only and does not constitute legal advice. The content herein is not a substitute for obtaining legal advice from a qualified attorney licensed in the appropriate jurisdiction. Viewing or relying upon this information does not create an attorney-client relationship. Readers should consult with legal counsel regarding their individual circumstances before taking any action based on this material.